Picture of Islet Holdings logo

ISHI Islet Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-1.85%
3m-3.16%
6m-11.63%
1yr-99.46%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-2166.36%
Operating Margin-109.38%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 200230th Sep 2003
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2002 / 2003

Blurred out image of Islet Holdings EPS forecast chart

Profile Summary

Islet Holdings Inc. is a biotechnology company, which is focused on cosmeceuticals. The Company is engaged in the research, development and commercialization of patented technologies in the field of transplantation in the therapy of people with conditions of insulin-dependent diabetes. The Company is developing intellectual property relating to hemp farming and extraction of cannabidiol (CBD) from hemp. Its technology constitutes methods for isolating, culturing, cryopreservation and immune-protection (microencapsulation) of islet cells. The Company's product candidates are intended for the treatment of insulin-dependent diabetes and are intended to be administered into the patient's abdominal cavity, where the transplanted islet cells will produce insulin in response to increase in blood glucose. The primary function of microencapsulation is to protect the islets from the host's immune system. The microcapsule coating is composed of layers of biocompatible materials.

Directors

Last Annual
September 30th, 2001
Last Interim
June 30th, 2002
Incorporated
December 10th, 1981
Public Since
April 21st, 1994
No. of Shareholders
620
No. of Employees
7
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
206,200,000

ISHI Share Price Performance

Similar to ISHI

Picture of Acusphere logo

Acusphere

us flag iconPink Sheets on Nasdaq

Picture of Adorbs logo

Adorbs

us flag iconPink Sheets on Nasdaq

Picture of Agentix logo

Agentix

us flag iconPink Sheets on Nasdaq

Picture of Agrios Global Holdings logo

Agrios Global Holdings

us flag iconPink Sheets on Nasdaq

Picture of Aida Pharmaceuticals logo

Aida Pharmaceuticals

us flag iconPink Sheets on Nasdaq

FAQ